Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in several upcoming virtual investor conferences. Key events include the 7th Annual Truist Securities Life Sciences Summit on May 4, the Bank of America Health Care Conference on May 13, the Morgan Stanley Asia Healthcare Conference on May 13-14, and the RBC Capital Markets Global Healthcare Conference on May 18. Live webcasts will be accessible on HOOKIPA's website, with replays available for 30 days. HOOKIPA is focused on developing innovative immunotherapeutics using its proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company focused on immunotherapeutics, announced its participation in the virtual Kempen Life Science Conference on April 21, 2021. The management team will host one-on-one meetings during the event. HOOKIPA is advancing a pipeline targeting virally mediated cancer antigens and infectious diseases, including its lead oncology candidates, HB-201 and HB-202, in Phase 1/2 trials. The company also collaborates with Gilead Sciences to explore functional cures for HIV and Hepatitis B infections, showcasing its innovative approach to immunotherapy.
HOOKIPA Pharma announced positive preliminary Phase 1 data for oncology candidates HB-201 and HB-202 targeting HPV16+ cancers. Key highlights include up to an 8% increase in circulating CD8+ T cells and significant immune activation, notably an increase in interferon-gamma. Presented at the AACR Annual Meeting, these results reinforce previous findings of anti-tumor activity. The ongoing Phase 1/2 study (NCT04180215) is exploring various dosing strategies with potential for major advancements in treatment options for metastatic HPV16+ cancers.
HOOKIPA Pharma reported a strong financial position with a cash balance of $143 million at year-end 2020, bolstered by a $80.9 million financing and collaboration revenue of $19.6 million from Gilead. The oncology candidate HB-201 demonstrated promising anti-tumor activity in HPV16+ cancers, while HB-101 showed effectiveness in reducing CMV viremia in kidney transplant patients. The company aims for additional clinical data in 2021, showcasing the potential of its proprietary arenavirus platform for immunotherapeutics.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to release its fourth quarter and full year 2020 financial results on March 18, 2021, before market opens. A live conference call will follow at 8:30 am EDT to discuss the results and provide a corporate update. HOOKIPA is focused on developing immunotherapeutics using its proprietary arenavirus platform, with candidates HB-201 and HB-202 in a Phase 1/2 trial for HPV 16-positive cancers, and HB-101 in a Phase 2 trial for CMV vaccination in kidney transplant patients. The company has also partnered with Gilead Sciences for HIV and hepatitis B research.
HOOKIPA Pharma (NASDAQ: HOOK) announced significant pre-clinical data showcasing their innovative 2-vector system for cancer treatment in the journal Cell Reports Medicine. This method demonstrated tumor-specific responses exceeding 50% of circulating CD8 T cells, resulting in tumor cures and long-term immunity. The alternating administration of arenaviral vectors showed no vector-neutralizing antibodies, indicating the possibility of repeated treatments. HOOKIPA is evaluating this technology in an ongoing Phase 1/2 clinical trial for HPV16+ cancers, with promising interim results expected by mid-2021.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available starting March 09, 2021, at 7:00 AM ET via a webcast on HOOKIPA's official website. The company is focused on developing immunotherapeutics using its proprietary arenavirus platform, targeting cancers and infectious diseases. Notably, their product candidates, HB-201 and HB-202, are in Phase 1/2 trials for HPV-positive cancers, while HB-101 is in a Phase 2 trial for kidney transplant patients.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion scheduled for 9:20 AM ET. This event will be accessible via a live audio webcast on HOOKIPA's website, alongside an archived replay available for 30 days post-event. HOOKIPA is advancing a new class of immunotherapeutics through its proprietary arenavirus platform, focusing on treatments for cancers and infectious diseases, including a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for a cytomegalovirus vaccine.
HOOKIPA Pharma announced the closing of its underwritten public offering, raising approximately $80.9 million through the sale of 3,910,000 shares of common stock at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each. The preferred shares are convertible into 1,000 common shares. The offering was managed by Morgan Stanley and SVB Leerink, with RBC Capital Markets as lead manager. Proceeds will likely support HOOKIPA's development of immunotherapeutics targeting infectious diseases and cancers.
HOOKIPA Pharma has announced a public offering of 3,400,000 shares of common stock priced at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each, aiming to raise approximately $75 million. The offering is set to close on December 11, 2020. The underwriters have an option to purchase an additional 510,000 shares. The funds are intended for advancing its proprietary arenavirus platform targeting infectious diseases and cancers. This offering is made under a shelf registration statement with the SEC.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
